Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 211, Issue 6, Pages 602-606Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2014.08.017
Keywords
nausea and vomiting; ondansetron; pregnancy
Categories
Funding
- Motherisk Program in Toronto
Ask authors/readers for more resources
Presently, 97.7% of prescriptions for the treatment of nausea and vomiting in pregnancy in the United States are with medications not labeled for use in pregnancy, not indicated for nausea and vomiting in pregnancy, and not classified as safe in pregnancy by the Food and Drug Administration. The use of ondansetron for nausea and vomiting in pregnancy has increased from 50,000 monthly prescriptions in 2008 to 110,000 at the end of 2013, despite unresolved issues regarding fetal safety and Food and Drug Administration warnings about serious dysrhythmias. In April 2013, the Food and Drug Administration approved the combination of doxylamine and pyridoxine, specifically for nausea and vomiting in pregnancy symptoms. Now that a safe and effective drug is available in the United States, there is no reason for women to be exposed to a drug of unproven maternal and fetal safety.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available